U.S., March 13 -- ClinicalTrials.gov registry received information related to the study (NCT07467772) titled 'Ph 2 Elacestrant in ER Positive Uterine Sarcomas' on Feb. 12.
Brief Summary: This study is to evaluate the efficacy and safety of elacestrant, in participants with advanced estrogen receptor (ER)-positive uterine sarcomas. The name of the study drug involved in this research study is:
-Elacestrant (a type of selective estrogen receptor degrader)
Study Start Date: Feb., 2026
Study Type: INTERVENTIONAL
Condition:
Uterine Sarcoma
Uterine Leiomyosarcoma
Endometrial Stromal Sarcoma
ESS
Perivascular Epithelioid Cell Tumors
Uterine Adenosarcoma
Uterine PEComa
Estrogen Receptor Positive Tumor
uLMS
Intervention:
DRUG: Elacestrant
Se...